Asterias Biotherapeutics, Inc. 4
4 · Asterias Biotherapeutics, Inc. · Filed Nov 28, 2016
Insider Transaction Report
Form 4
Spink Katharine E.
Vice President & COO
Transactions
- Exercise/Conversion
Options to Purchase Common Stock
2016-11-23+2,500→ 195,000 totalExercise: $2.34From: 2013-03-10Exp: 2020-03-09→ Common Stock (2,500 underlying) - Sale
Common Stock
2016-11-23$5.41/sh−2,500$13,525→ 0 total - Exercise/Conversion
Common Stock
2016-11-23$2.34/sh+2,500$5,850→ 2,500 total
Footnotes (3)
- [F1]The shares reported herein were sold pursuant to a Rule 10b5-1 Plan adopted by the reporting person.
- [F2]Excludes 7,658 Restricted Stock Units payable in shares of the Issuer's common stock that have not vested as of the date of this Report.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.40 to $5.45, inclusive. The reporting person undertakes to provide to any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.